TAS::75 0849::TAS THE MAIN TECHNICAL OBJECTIVE OF THIS CONTRACT IS TO GENERATE

Cancer Therapeutics Laboratories, Inc., Los Angeles CA

Investigators

Abstract

In the last decade, monoclonal antibody immunotherapy has established itself as a front-line treatment of human cancer. One such antibody, Erbituz (cetuzimab), has been used to treat epidermal growth factor receptor positive (EGFR+) tumors due to its ability to inhibit tumor growth by blocking EGFR signaling required for cell proliferation. In this proposal, a generic anticody, designated ch225, will be generated to provide the medical community with a cost effective alternative product for Erbitux.